Search
forLearn
5 / 801 resultslearn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
learn nicotinamide
learn Calcipotriene
learn Latanoprost
glaucoma medication with hair follicle stimulant effects
Research
5 / 1000+ resultsresearch Teneligliptin-induced hair loss: A case report
Increasing Teneligliptin on his own caused a man's hair loss, which stopped when he ceased the medication.
research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
Pranlukast and mirabegron may work as new diabetes drugs.
research Linagliptin-Associated Alopecia and Bullous Pemphigoid
Linagliptin may cause hair loss and skin blisters.
research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
Community Join
5 / 1000+ resultscommunity Positive Hair Result in Patient using Tirzepatide
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
community Upcoming Setipiprant clinical trials hint at systemic daily dosage
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
community Winlevi (clascoterone 1%) anyone trying it
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
community Follicept and others - the future of preserving what you have - sign up
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.
community Setipiprant trial results
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.